Although there are many drugs that are effective in relieving short- or long-term insomnia, their mechanisms are well established (e.g., eszopiclone (Wilt et al., 2016; Rösner et al., 2018)—acting on BDZ receptors and enhancing GABA receptor action within the central nervous system), they do not act by affecting the CNR1-PI3K-AKT signaling pathway effects. This evidence concerns the gene CNR1 and insomnia measurement.